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Multiple myeloma is a B cell malignancy. Recently, it has been demonstrated that bone marrow samples of patients with
multiple myeloma display an enhanced angiogenesis. The mechanisms involved seem to be multiple and complex. We here
demonstrate that the murine 5T multiple myeloma models are able to induce angiogenesis in vitro by using a rat aortic ring
assay and in vivo by determining the microvessel density. The rat aortic rings cultured in 5T multiple myeloma conditioned
medium exhibit a higher number of longer and more branched microvessels than the rings cultured in control medium. In
bone marrow samples from 5T multiple myeloma diseased mice, a statistically signiﬁcant increase of the microvessel density
was observed when compared to bone marrow samples from age-matched controls. The angiogenic phenotype of both 5T
multiple myeloma cells could be related, at least in part, to their capacity to produce vascular endothelial growth factor. These
data clearly demonstrate that the 5T multiple myeloma models are good models to study angiogenesis in multiple myeloma
and will allow to unravel the mechanisms of neovascularisation, as well as to test new putative inhibitors of angiogenesis.
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Multiple myeloma (MM) is a B cell neoplasm with three major
characteristics: the expansion of malignant plasma cells mainly
localised in the bone marrow, the presence of a monoclonal serum
immunoglobulin and the activation of osteoclasts leading to osteo-
lysis. The disease occurs mainly at older age and is still incurable in
spite of the progress in treatment. Recently, it has been demon-
strated that angiogenesis or neovascularisation is also involved in
MM disease and its extent, as measured by microvessel density
(MVD) of the bone marrow, correlated well with the activity of
MM (Vacca et al, 1994). The human U266 MM cell line and bone
marrow plasma cells from patients with active MM display a strong
angiogenic potential (Vacca et al, 1998, 1999; Laroche et al, 2001).
Moreover, bone marrow MVD also seems to be a prognostic factor
of survival in MM patients (Sezer et al, 2000).
Angiogenesis is a complex process in which new blood vessels
develop from pre-existing ones. It is controlled by a balance
between pro-angiogenic and anti-angiogenic factors (Talks and
Harris, 2000). While this balance is highly regulated in physiologi-
cal circumstances such as reproduction, development and wound
repair, an imbalance is associated with a variety of disorders
including cancers (Folkman and Shing, 1992; Compagni and Chris-
tofori, 2000). Tumour growth and metastasis are dependent on
new blood vessel formation (Kim et al, 1993; Folkman, 1995).
The vessels provide nutrients and a route by which tumour cells
exit the primary site and enter the blood stream (Zetter, 1998).
Among the various angiogenic stimulators, an important factor
involved in normal and pathological angiogenesis is vascular
endothelial growth factor (VEGF) (Ferrara, 1999b; Carmeliet and
Collen, 2000) which is able to stimulate vascular permeability
and is an endothelial cell speciﬁc mitogen (Connolly et al, 1989).
By alternative splicing of a single gene, several VEGF isoforms
can be produced (Shima et al, 1996). VEGF is secreted by many
tumour cell lines in vitro and its mRNA is upregulated in the vast
majority of human tumours (Ferrara, 1999a).
To investigate the importance and the underlying mechanisms
of angiogenesis in the development of MM, an in vivo model is
required. Therefore we selected the murine 5TMM models. We
have used two MM models, which initially originated sponta-
neously in ageing C57BL/KaLwRij mice (Radl et al, 1979).
Tumour cells from diseased mice were isolated from the bone
marrow and transplanted into young syngeneic recipients by intra-
venous injection. By this way, several 5TMM models were
developed (Radl et al, 1979) with similar characteristics as the
human disease: the disease occurs spontaneously at older age, the
MM cells are localised in the bone marrow, tumour load can be
assessed by paraproteinaemia, osteolytic lesions develop and the
molecular mechanisms are like in humans (Vanderkerken et al,
1996; Radl et al, 1988; Asosingh et al, 2000). As previously
reported, the 5T2MM model more closely represents human
MM, characterized by a moderate progressive course of the disease
and induction of osteolytic lesions, while the 5T33MM model
represents an aggressive, rapidly progressive variant (Vanderkerken
et al, 1997; Radl et al, 1988). Therefore, the 5T2MM and 5T33MM
models are good in vivo murine models of myeloma which mimic
different aspects of the human disease (Asosingh et al, 2000).
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www.bjcancer.comThe aim of this study was to study the ability of 5T2MM and
5T33MM cells to induce angiogenesis in the bone marrow, as do
human MM cells. The angiogenic potential of 5T2MM and
5T33MM cells was assessed both in vitro, in the aortic ring assay,
and in vivo, by determining the microvessel density in bone
marrow samples of control mice and 5T2MM and 5T33MM-
diseased mice. The understanding of neovascularization mechan-
isms in MM may provide further beneﬁts for both diagnosis and
therapy.
MATERIALS AND METHODS
Mice
C57BL/KaLwRij mice were purchased from Harlan CPB (Horst,
The Netherlands). They were housed and treated following the
conditions approved by the Ethical Committee for Animal Experi-
ments, VUB (License no. LA1230281). The animal ethics meet the
standards required by the UKCCCR Guidelines (UKCCCR, 1998).
5TMM models
The in vivo growing 5T2MM and 5T33MM originated initially
spontaneous in ageing C57BL/KaLwRij mice and have since been
propagated into young syngeneic recipients by intravenous transfer
of the diseased bone marrow (Radl et al, 1979). The tumour take
was followed up by protein electrophoresis of the serum samples
(Vanderkerken et al, 1997). Mice were killed when a serum para-
protein concentration of 10 mg ml
71 was reached. The MM cells
in the bone marrow were isolated and puriﬁed as previously
described (Vanderkerken et al, 1999). Bone marrow was ﬂushed
from the hind legs. The isolated cells were suspended in RPMI-
1640 medium (Gibco, Life Technologies, Gent, Belgium) supple-
mented with penicillin/streptomycin, glutamine, MEM and
sodium pyruvate (Gibco). After washing, mononuclear cells were
isolated by Lympholyte M (Cedarlane, Hornby, Canada) gradient
centrifugation at 1000 g for 20 min. Subsequently, the cells were
further puriﬁed on a Percoll (Pharmacia, Uppsala, Sweden) 60%
(for 5T2) and 70% (for 5T8); gradient centrifugation at 450 g
for 25 min. Cells were stained with anti-idiotype antibodies and
purity was assessed by ﬂow cytometry (Vanderkerken et al,
1997). The 5TMM cells (1610
6 cells ml
71) were cultured in
serum-free MCDB131 medium (an optimised medium for micro-
vascular endothelial cell growth) or were immediately snap-frozen
for RNA isolation. After 48 h, conditioned media were collected.
Assessment of angiogenesis by rat aortic ring assay
Angiogenesis was studied by culturing aortic explants in three-
dimensional matrix gels according to the procedure of Nicosia
and Ottinetti (1990). Thoracic aortas removed from 8- to 12-
week-old male Fisher-344 rats were immediately transferred to a
culture dish containing cold serum-free Minimum Essential
Medium (MEM, Life Technologies). The periaortic ﬁbroadipose
tissue was carefully removed with ﬁne microdissecting forceps
and iridectomy scissors paying special attention not to damage
the aortic wall. Aortic rings (1 mm-long) (approximately 20 per
aorta) were sectioned and extensively rinsed in ﬁve consecutive
washes of MEM medium. Ring-shaped explants of rat aorta were
then embedded in gels of rat tail interstitial collagen (1.5 mg ml
71)
as previously described by Montesano et al (1983). The ﬁnal
collagen solution was obtained by mixing 7.5 volumes of collagen
(2 mg ml
71) (Collagen R, Serva, Heidelberg, Germany) with one
volume of 106MEM, 1.5 volumes of NaHCO3 (15.6 mg ml
71)
and approximately 0.1 volume NaOH (1 M) to adjust the pH to
7.4. The collagen gel cultures were ﬁrst prepared in cylindrical
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Figure 1 Photomicrographs of rat aortic rings cultured in collagen gels in the presence of serum-free medium (A), serum-free medium supplemented
with 20 ng ml
71 rVEGF165 (B), 5T2MM conditioned medium (C), 5T33MM conditioned medium (D). Photomicrographs from one experiment, repre-
sentative of there, are shown.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(5), 796–802agarose wells (Nicosia and Ottinetti, 1990) and kept in triplicates at
378C in 100 mm diameter Petri dishes (bacteriological polystyrene,
Falcon, Becton Dickinson, Lincoln Park, NJ, USA). Each dish
contained either 30 ml of MCDB131 (Life Technologies) supple-
mented with 25 mM NaHCO3, 1% glutamine, 100 U ml
71
penicillin and 100 mgm l
71 streptomycin or MCDB131 medium
conditioned by 5T2MM or 5T33MM cells. As positive control
human recombinant VEGF165 (20 ng ml
71) was added to the
medium. The cultures were kept at 378C in a humidiﬁed environ-
ment for 1 week and examined by phase contrast microscopy with
an Olympus microscope at the appropriate magniﬁcation. Image
analysis was performed on a WorkStation Sun SPARC30, using
the software ‘Visilog5.0’ from Noesis. We used an improved
computer-assisted image analysis (Blacher et al, 2001) which allows
automatic measurements of the geometrical and morphological
parameters. After generation of binary image, the following auto-
matic measurements were performed: the quantiﬁcation of
microvessels according to the vascular complexity, i.e. the determi-
nation of the microvessel distribution given by the total number of
intersections of microvessels (Ni) in function to the distance to the
aortic ring. The Ni value at the ﬁrst step of the grid gives the
number of microvessels (Nv). The grid step at which the last
Ni=0 is measured gives the maximal microvessel length (Lmax).
The sum of additional intersections detected at each step of the
grid gives the total number of branching (Nb). Statistical para-
meters have been calculated to describe the distribution of Ni.
The mean distribution (D) and the standard deviation correspond
to the distance from the explant at which Ni reaches its mean
value. The mode (d) corresponds to the distance from the explant
at which most cells migrated. The skewness (sk) describes the
symmetry of the distribution and the kurtosis (k) describes how
ﬂat or peaked the distribution is.
Assessment of angiogenesis by bone marrow microvessel
density
Long bones, vertebrae and ribs of age-matched control, 5T2MM
and 5T33MM diseased C57BL/KaLwRij mice were ﬁxed in zinc
ﬁxative (0.1 M Tris buffer, pH 7.4, 3 mM calcium acetate,
0.027 M zinc acetate and 0.037 M zinc chloride) for 24 h and decal-
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Figure 2 Determination of the number of microvessel intersections (Ni) in function of the distance to the aortic ring. Histograms have been constructed
for control (A), VEGF (B), 5T2MM (C), 5T33MM (D). Statistical parameters are indicated for each histogram. D: distance from the explant at which Ni
reaches its mean value; d: distance from the explant at which most cells migrated; sk40 indicates that most cells migrate at distances lower than D;
k: sharpness of the cell distribution around d.
Angiogenesis in a murine multiple myeloma model
E Van Valckenborgh et al
798
British Journal of Cancer (2002) 86(5), 796–802 ã 2002 Cancer Research UKciﬁed in FE10 (0.27 M EDTA, 0.3 M NaOH, 4% formalin) for 3
days. The material was embedded in parafﬁn and 5 mm longitudi-
nal sections throughout the whole bones were made with a rotation
microtome (Microm HM335, Germany). One slide was stained
with haematoxylin and eosin, the consecutive slide and two addi-
tional slides with a 50 mm distance from each other were
immunostained for CD31 in order to visualise the blood vessels
and sinusoids in the bone marrow.
For immunostaining, the endogenous peroxydase was quenched
by incubating the slides with a 50 ml methanol, 0.5 ml H2O2
(30%) solution for 30 min. Trypsinisation (Trypsin 109827, Boeh-
ringer Mannheim, IN, USA) for 20 min, at 378C was used for
antigen retrieval. The slides were preincubated with normal goat
serum for 30 min. The primary antibody (PECAM-1, Becton Dick-
inson PharMingen, LA, USA) was incubated overnight at 48Ca ta
dilution of 1 out of 100. As secondary antibody, a biotin-conju-
gated goat anti-rat speciﬁc polyclonal immunoglobulin (554014,
Becton Dickinson PharMingen, LA, USA) was used at a dilution
of 1 out of 100. The TSA (Tyramide Signal Ampliﬁcation) (NEN
Life Science Products, Boston, MA, USA) was used to enhance
the signal intensity. Chromogenic visualisation was accomplished
through the use of a streptavidin-horseradish peroxydase conjugate,
followed by diaminobenzidin.
The haematoxylin and eosin sections of the bone marrow were
screened for the presence of myeloma cells, with a light microscope
(Axiolab, CarlZeiss, Germany). For quantiﬁcation of angiogenesis,
areas with the highest density of blood vessels (hot spot) were
selected on sections immunostained for CD31. The number of
blood vessels was counted per 0.22 mm
2 using a microscope
eyepiece graticule (610 ocular and 620 objective). The microves-
sel density was independently evaluated by two observers.
Detection of mRNA for VEGF
Total RNA from 5610
6 puriﬁed 5T2MM and 5T33MM cells was
isolated using the SV total RNA isolation system (Promega
Corporation, Madison WI, USA) according to the manufacturer’s
instructions. The concentration and purity of RNA was determined
by spectrophotometric measurement (Gene Quant II, Pharmacia
Biotech, Cambridge, UK).
One to 5 mg of total RNA was converted into cDNA by the
superscript ﬁrst-strand synthesis system (Gibco, Life Technologies)
using random hexamers as primers. The cDNA was used as
template for PCR in a 25 ml reaction containing: PCR buffer,
2m M magnesium chloride, 0.2 mM dNTP, 0.5 mM of each primer
and 0.625 U Taq polymerase. The sense and antisense primers used
for the ampliﬁcation of the known splice variants of mouse VEGF
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Figure 3 CD31 immunostaining of bone marrow from a rib of a control
mouse (A), from a rib of a 5T2MM diseased mouse (B) and from a femur
of a 5T33MM diseased mouse (C).
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Figure 4 Number of blood vessels counted in the bone marrow of
control mice, 5T2MM and 5T33MM diseased mice. The blood vessels were
visualised by an immunostaining for CD31. Mean+s.e. values of 14 animals
per group are shown. *Indicates signiﬁcant difference (P50.001) compared
with control.
Angiogenesis in a murine multiple myeloma model
E Van Valckenborgh et al
799
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(5), 796–802are 5'-CCTGGTGGACATCTTCCAGGAGTA-3' and 5'-
CTCACCGCCTCGGCTTGTCACA-3', respectively. Forty PCR
cycles were performed preceded by a denaturation step at 958C
for 2 min followed by 20 s at 948C, 20 s at 668C and 30 s at
728C. The predicted size of the ampliﬁed products was 479 bp
for VEGF188, 407 bp for VEGF164 and 275 bp for VEGF120 (Haji-
tou et al, 2001). PCR products were analysed by electrophoresis on
a 1.5% low-melting agarose gel. The PCR samples were cloned into
the pCRII vector (Invitrogen, San Diego, CA, USA) and sequenced
with vector-speciﬁc primers using the Sequenase version 2.0 DNA
sequencing kit (USB Corporation, Cleveland, OH, USA).
Detection of VEGF protein
The secretion of VEGF by the 5TMM cell lines in serum-free
conditioned media (48 h) was quantiﬁed by an enzyme-linked
immunosorbent assay (ELISA, R&Dsystems, Wiesbaden, Germany)
according to the manufacturer’s instructions. Each sample was
performed in duplicate and two independent experiments were
done.
Statistical analysis
For statistical analysis the unpaired student’s t-test was used. P-
values50.05 were considered as signiﬁcant.
RESULTS
5TMM cells induce angiogenesis in vitro
The angiogenic potential of the 5T2MM and 5T33MM cells was
tested in the in vitro rat aortic ring assay. Aortic rings were
cultured in the presence of serum-free MCDB131 medium or
MCDB131 medium conditioned by 5T2MM or 5T33MM cells.
As positive control human recombinant VEGF165 was added to
the medium. After 1 week, the rings cultured in the presence of
5T2MM (Figure 1C) or 5T33MM (Figure 1D) conditioned media
(Figure 1A) exhibit more capillaries than those cultured in control
medium. Interestingly, in the presence of 5T33MM conditioned
medium, the total number of microvessels (Nv=38) was two-fold
higher than in control conditions (Nv=20). The addition of
5T2MM conditioned medium induced a less pronounced, but still
statistically signiﬁcant effect on microvessel outgrowth (Nv=24). In
the presence of both media conditioned by myeloma cells, the
maximal microvessel length was 20% enhanced (Lmax=1.0 mm vs
0.85 mm in control conditions). The vascular network complexity
was more precisely studied by statistical analysis according to the
methodology described by Blacher et al (2001) (Figure 2). The
broadness of the histogram obtained with both conditioned media
indicates that microvessel networks were more branched than in
control conditions. Indeed, the Ni distribution of 5T2MM and
5T33MM condition had a peak (k % 0) nearby the aortic ring
and decreased less steeply (sk=0.65 for 5T2MM and 0.72 for
5T33MM) than in control conditions (sk=1.10). This indicates that
myeloma conditioned media enhanced the vascular network
complexity which are then characterized by more branched vessels
(Figure 2A).
Assessment of microvessel density in the bone marrow
Using an eye-piece graticule the area with the highest density of
blood vessels was selected, discarding the area near the growth
plate since this area, as distinctly observed in the non-invaded
marrow, has physiologically a higher blood vessel density. When
compared to normal bone marrow, the sinusoids were more
compressed (probably a mechanical effect) in the tumour-invaded
marrows. When dilated sinusoids were observed in invaded
marrows, they were massively ﬁlled with tumour cells. Since the
lumen of the sinusoids belongs to the extramedullary compartment
this ﬁnding conﬁrms the presence of circulating tumour cells. As
previously observed (Vanderkerken et al, 1997), the 5T33MM cells
were more blastic (centrally located nuclei, distinctive nucleoli)
compared to 5T2MM cells in which the plasmacytic differentiation
was more readily observed (eccentric location of the nucleus,
clumped chromatin).
In both 5T2MM and 5T33MM invaded bone marrows, we
observed a statistically signiﬁcant increase in blood vessel density
as compared to non-invaded controls (Figures 3 and 4). The hot
spots coincided with sites of massive invasion.
Expression and secretion of VEGF by the 5T2MM and
5T33MM cells
Since VEGF is one of the most important pro-angiogenic factors,
we investigated whether 5TMM cells secrete VEGF. The expression
of VEGF transcripts was determined by RT–PCR (Figure 5). The
positive control (murine kidney) expresses the three VEGF
isoforms. The 5T2MM and 5T33MM cells express VEGF transcripts
corresponding to the two lower molecular weight isoforms,
VEGF164 and VEGF120. This was conﬁrmed by sequencing the
two transcripts (Claffey et al, 1992; Shima et al, 1996). The secre-
tion of VEGF by both cell lines was further assessed by ELISA. The
concentration of VEGF in culture supernatants of the 5T2MM and
5T33MM cells ranged between 100 and 160 pg ml
71.
DISCUSSION
Recently, it was postulated that neovascularization may play an
important role in haematological malignancies (Bertolini et al,
2000; Mangi and Newland, 2000). It was suggested that, like in
solid tumours, the progression of MM takes place in two phases.
Nonactive MM and monoclonal gammopathies of undetermined
signiﬁcance (MGUS) might represent the prevascular phase,
whereas active MM might correspond to the vascular phase (Vacca
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Marker 5T33MM 5T2MM Murine Negative
kidney control
Figure 5 Analysis of VEGF expression in the 5TMM cells by RT–PCR. cDNA from puriﬁed myeloma cells were subjected to speciﬁc VEGF ampliﬁcation.
The ampliﬁcation products were detected as a band of 275 bp for VEGF120, 407 bp for VEGF164 and 479 bp for VEGF188. Murine kidney was used as
positive control for the three isoforms of VEGF. This experiment is representative for two experiments.
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ized ﬁrst by the stimulation of endothelial cells by angiogenic
factors, and then by the production of proteolytic enzymes, such
as matrix metalloproteinases (MMPs) and urokinase plasminogen
activator (uPA). These enzymes are involved in the degradation
of the basement membrane and the extracellular matrix, and
promote the migration and proliferation of endothelial cells to
form a new blood vessel (Moses, 1997; Zetter, 1998). In human
MM, VEGF and bFGF are secreted by tumour cells and the
concentrations of these angiogenic factors are higher in more
advanced disease (Vacca et al, 1998; Bellamy et al, 1999; Dankbar
et al, 2000; Di Raimondo et al, 2000; Sezer et al, 2000; Van Riet
et al, 2000). MM cells also secrete MMPs (Barille ￿ et al, 1997,
1999; Vanderkerken et al, 2000) and uPA (Hjertner et al, 2000)
and their conditioned medium is able to stimulate the proliferation
and migration of endothelial cells (Vacca et al, 1998, 1999). These
ﬁndings suggest that the MM cells can induce angiogenesis. The
ability of medium conditioned by plasma cells from MM patients
to stimulate neovascularisation in the chorioallantoic membrane
assay supports this hypothesis (Vacca et al, 1998, 1999). These
recent insights disclose new possible therapeutic targets. Interest-
ingly, the anti-angiogenic drug, thalidomide, has been reported
to be effective in patients with refractory MM (D’Amato et al,
1994; Singhal et al, 1999). The development of drugs acting on
different levels of angiogenesis can thus be considered as a promis-
ing pathway. This research inevitably requires good in vitro and in
vivo experimental models. In the present study, we demonstrate
that the 5T2MM and 5T33MM murine multiple myeloma models
are interesting in vivo models of angiogenesis. Both cell lines are
able to induce in vitro and in vivo angiogenesis. This could be,
at least in part, related to their capacity to produce VEGF as
demonstrated by RT–PCR and ELISA. These data indicate that
MM cells have, at least, the potential to induce the ﬁrst step of
neovascularisation, namely the stimulation of endothelial cells.
The ability of both 5T2MM and 5T33MM cells to induce in
vitro angiogenesis was measured in the rat aortic ring assay. The
microvessels branched, anastomosed, developed lumina and
formed complex networks as initially described by Nicosia and
Ottinetti (1990). Compared to control condition, a more complex
microvessel outgrowth occurred when the rings were cultured in
the presence of media conditioned by 5T2MM or 5T33MM cells.
However, the network of blood vessels was less complex than the
one induced by recombinant VEGF, as assessed by our original
method of vessel quantiﬁcation based on computer-assisted image
analysis (Blacher et al, 2001). In the rat aortic ring assay a dose-
dependent effect of VEGF on microvascular network complexity
was evidenced by Blacher et al (2001). The much lower VEGF
concentration in 5T2MM and 5T33MM conditioned media than
the concentration of recombinant VEGF added to the medium of
the positive control can explain the difference in network complex-
ity. The MVD in the bone marrow from diseased and control
animals was compared in order to investigate the in vivo angiogen-
esis. To achieve a reliable counting of the bone marrow blood
vessels several factors had to be fulﬁlled: representative samples,
optimal ﬁxation and decalciﬁcation, thin sections and a sensitive
immunohistochemical staining of the blood vessels. Whole bones
were collected at different sites of the skeleton; ﬁxation and decal-
ciﬁcation methods were optimised. Immunostaining for the CD31
antigen of the blood vessels in the BM of 5T2MM and 5T33MM
diseased mice revealed a signiﬁcantly higher MVD in the diseased
animals compared to the control animals. The higher angiogenic
potential of the 5T33MM model can be due to the more aggressive
growth of the 5T33MM cells compared to the 5T2MM cells
(Vanderkerken et al, 1997).
Based on their in vivo and in vitro angiogenic potential and their
capacity to produce VEGF, we conclude that the two 5TMM
models are suitable for the study of multiple myeloma neovascular-
ization. These models can now be used to unravel the multistep
process of neovascularization and to test new angiogenic inhibitors.
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